^
Association details:
| Biomarker: | POLE E790Q + ERBB2 amplification + TMB-H |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer
Published date:
03/05/2022
Excerpt:
We aimed to report the first case of programmed death-ligand 1 (PD-L1)-negative mBC presenting with high TMB and POLE mutations, in which a complete response to 5 cycles of chemotherapy and 1 year of pembrolizumab and trastuzumab was noted after failing several lines of HER2-targeted therapies....The results revealed the existence of a total of 19 somatic mutations, including POLE E790Q mutation, ERBB2 amplification, and high TMB....To date, this patient has undergone 5 cycles of treatment of nab-paclitaxel and 2 years of trastuzumab and pembrolizumab with acceptable tolerability and achieved complete response.
DOI:
10.1093/oncolo/oyac027
